XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
Rituximab shows potential for treatment of lymphoma
Nov 5, 2004, 13:11, Reviewed by: Dr.



 
Results from a recent study indicate that patients under the age of 60 with diffuse large B-cell non-Hodgkin�s lymphoma who are treated with both the antibody therapy rituximab and chemotherapy had improved survival rates when compared with patients treated with chemotherapy alone. The lead author of the study, Dr. Michael Pfreundschuh, presented these findings at the American Society of Clinical Oncology�s 2004 Annual Meeting. The randomized study, which was conducted in eighteen countries, is unique because it is one of the first to focus on the use of rituximab in patients who are under 60 years old�previous studies have reported positive results for elderly patients. As explained by Dr. Pfreundschuh at the meeting, individuals who were treated with a combination of rituximab and chemotherapy achieved the best results ever reported for young patients with this disease. This treatment group had a significantly higher complete remission rate and a lower rate of progressive disease than patients who were treated with only chemotherapy. This indicates that there is a potential for this form of lymphoma to be considered curable in this set of patients if the study�s positive results can be consistently replicated. Dr. Pfreundschuh is the Director of Medical Oncology at Saarland University Medical School, Homburg, Germany, and is a member of the Institute�s Cancer Antigen Discovery Collaborative. He was the recipient of the 2000 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. 

- Cancer Research Institute
 

Dr. Pfreundschuh�s presentation may be viewed online

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 



Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us